Fedora Pharmaceuticals Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Esperion Hooks Daiichi Sanky

Device Transactions Device financing during 2015's third quarter reached $1.4 billion, a 22% dip from Q2's $1.8 billion total. ( See Exhibit 1. ) Late-stage venture capital rounds represented most of

Point-of-care testing is back in style. The concept of developing technologies that can rapidly diagnose disease or yield other important medical information, and do so without highly trained laborato

The looming antibiotics resistance crisis threatens the very underpinning of modern medicine and has the potential to be more lethal than AIDS, but the lack of viable business models and political wil